Hemispherian
Oslo · Founded 2020 · Norway corporation · 1 known investors
Find your way into Hemispherian
256 people in our graph share verified history with the Hemispherian team — schools, employers, funds. One of them is your warm intro.
Ottounlockedknows Zeno Albisser · together at BI Norwegian Business School (overlapped)
×3knows the team · via Nokia
×4knows the team · via University of California, Berkeley, Haas School of Business
×3knows the team · via University of Oslo
knows the team · via The Qt Company
Hemispherian is a clinical-stage pharmaceutical company developing small molecule drugs that target the TET2 enzyme as targeted therapies for aggressive cancers. Its lead compound GLIX1 is entering clinical development for glioblastoma, a cancer of the central nervous system.
Founders & leadership
Hemispherian was founded in 2020 by Terezia Prikrylova, Adam Brian Robertson, and Zeno Albisser.
TP
Terezia PrikrylovainCo-founder · Chief Operating Officer2019–2026Terezia Prikrylova co-founded Hemispherian in Oslo in 2019 and led the development of a TET2-targeting small molecule compound through preclinical and regulatory stages, including securing FDA IND clearance and two Orphan Drug Designations. She holds a PhD in molecular biology and has expertise in preclinical research management, regulatory submissions, and drug development programme governance.
AB
Adam Brian RobertsonCo-founder
ZA
Zeno AlbisserinCo-founder · Chief Executive OfficerZeno Albisser founded and leads Hemispherian, a clinical-stage pharmaceutical company developing small molecule drugs targeting the TET2 enzyme for cancer treatment. He previously worked as a software engineer and engineering manager.
Board
AM
Anett Monika DiazBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$107.7K disclosed across 2 rounds · 2020–2022
▶$50KraisedMay 2022 · 2 investors · PharmaceuticalsRule 506(c)
▶$50KraisedMay 2022 · 2 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Masha Paule Nathalie Legris StrommeDirector
- Dallas Christian HackDirector
- Terezia PrikrylovaPromoter
- Cecilie Stenstadvold SverdrupDirector
- Adam Brian RobertsonPromoter
- Steven John PowellDirector
- Zeno AlbisserExecutive Officer
- Offering amount
- $50K
- Amount sold
- $50K
- Minimum investment
- $10K
- Proceeds to insiders
- $10K
- First sale
- Apr 2022
- Incorporated
- Corporation, Norway, 2020
- Federal exemptions
- 06c, 4a5
▶$57.7KraisedJan 2021 · 2 investors · PharmaceuticalsRule 506(c)
▶$57.7KraisedJan 2021 · 2 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Terezia PrikrylovaDirector
- Adam Brian RobertsonDirector
- Zeno AlbisserExecutive Officer, Director
- Anett Monika DiazDirector
- Offering amount
- $57.7K
- Amount sold
- $57.7K
- Minimum investment
- $20K
- Proceeds to insiders
- $10K
- First sale
- Dec 2020
- Incorporated
- Corporation, Norway, 2020
- Federal exemptions
- 06c, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Hemispherian do?
- Hemispherian is a clinical-stage pharmaceutical company developing small molecule drugs that target the TET2 enzyme as targeted therapies for aggressive cancers. Its lead compound GLIX1 is entering clinical development for glioblastoma, a cancer of the central nervous system.
- Who founded Hemispherian?
- Hemispherian was founded by Terezia Prikrylova, Adam Brian Robertson, Zeno Albisser in 2020.
- Who are Hemispherian's investors?
- Hemispherian's investors include Bif.
- How much funding has Hemispherian raised?
- Hemispherian has disclosed $107.7K raised across 2 rounds.
- Where is Hemispherian headquartered?
- Hemispherian is headquartered in Oslo.